← All trials
NCT05171075
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2022
- Primary completion
- Sep 30, 2023
- Completion date
- Jun 30, 2024
- First posted
- Dec 28, 2021
- Last posted
- Dec 16, 2022
- Enrollment
- 1020
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anthos Therapeutics, Inc.Lead sponsor
- ItreasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.